Our data suggest that FOXO3 acetylation by EP300 could be a potential marker for the identification of tumors that are likely to be sensitive to these drugs and indicate a novel therapeutic strategy to overcome lapatinib resistance in HER2-positive breast cancers. This evidence concerns the gene ERBB2 and breast carcinoma.